Most Indian doctors buy their first life-insurance policy in their late twenties, often immediately after starting their first salaried role. The policy is almost always an endowment plan or a money-back scheme. The seller — typically a family LIC agent or a junior banker — frames the product as both insurance and investment. The doctor signs the form, pays the first premium, and feels the satisfaction of a responsible financial decision well-made.
The decision is, financially, almost always wrong.
The structural difference, plainly
A term life policy is pure insurance. You pay a small annual premium; in exchange, your family receives a large lump-sum if you die during the policy term. If you survive the term, the policy pays nothing, and your premium has gone to insure against an event that did not occur. The product is austere and unambiguous.
An endowment plan is insurance bundled with savings. You pay a much higher premium; some of it covers the death benefit; most of it is invested by the insurer in low-risk debt instruments. After 20-25 years, the insurer returns your accumulated investment, plus a "bonus", to you (or your beneficiary in case of death). The product feels generous because the premium "isn't wasted".
The marketing makes endowment plans feel like the better deal. The arithmetic says otherwise.
The arithmetic, run cleanly
Take a 30-year-old doctor with a household need for ₹2 crore of life cover.
Endowment Path. A ₹2 crore endowment plan costs roughly ₹15-18 lakh in annual premium. Over 25 years, the doctor pays roughly ₹4 crore in total. At maturity, they receive somewhere around ₹5-6 crore. The implied IRR — after the cost of the embedded insurance — is approximately 4-5%.
Term + Investment Path. A ₹2 crore pure term policy for the same doctor costs about ₹35,000 a year (sometimes less). The doctor pays the same total annual outflow as in Path A — ₹15-18 lakh. The first ₹35,000 goes to the term cover. The remaining ₹14.5-17.5 lakh is invested in a balanced equity-debt portfolio at, say, 10% nominal. Over 25 years, the investment portion grows to ₹16-19 crore.
The same total outflow. The same actual life cover. Three times the terminal wealth.
The doctor on Path B, in addition, retains liquidity — the investment portfolio is accessible at any time, without surrender charges. The doctor on Path A is locked in for 25 years, with substantial penalties for early exit.
This is not a controversial calculation. The math is run by every insurance regulator in every developed market, and it has informed why pure term cover dominates new life-insurance sales in those markets. India is a lagging adoption case for cultural and distribution reasons — not for analytical ones.
Why the wrong answer keeps winning
If the math is so clear, why does the typical Indian doctor still own endowment policies and not term?
1. Term is profoundly under-marketed. Term cover pays the agent a low, one-time commission. Endowment pays a high, multi-year commission. The economics of distribution explain almost everything about which products get pushed.
2. Indian families have a cultural preference for "money coming back". The idea that the premium is "wasted" if the policyholder survives is uncomfortable, even though survival is the intended outcome. The phrase doctors hear in family conversations — "at least you'll get something back" — is a rhetorical victory for the endowment industry over arithmetic.
3. The seller is rarely a stranger. The agent is often a family contact. The doctor, even if they understand the math, is reluctant to disappoint them. The premium signing is a relationship event as much as a financial one.
A practical doctor's approach
In our practice, we counsel new doctors in the same sequence:
- First, buy pure term cover sized to actual family need (typically 10-15× annual income for a 30-year-old).
- Second, buy disability cover for income replacement until at least age 60.
- Third, max out tax-advantaged investment vehicles — PPF, NPS, ELSS as relevant.
- Fourth, build a regular SIP into a balanced portfolio for everything else.
If, after all of the above, the doctor still has surplus they want to lock away — and if their tax bracket genuinely benefits from it — we can have a conversation about endowment plans for the very specific role they sometimes play in tax-efficient inheritance. For most doctors at most income levels, that conversation never gets to a "yes".
The simplest test
If a friend or relative offers you an endowment plan, ask them this: "What's the IRR of this plan, calculated after the cost of the embedded insurance, expressed as a percentage?"
If they cannot answer, they have not done the math. If they can, and the answer is below the post-tax return of a balanced mutual fund portfolio over the same horizon, the product is sub-optimal regardless of the relationship.
Saying no to a friend with a 4.8% endowment plan is uncomfortable. It is not, however, expensive. The lifetime cost of the discomfort is around ₹50,000 of relationship awkwardness. The lifetime cost of the wrong policy is ₹3-5 crore. Most doctors will quietly pay the second cost rather than absorb the first. Their advisors, if they have them, should help them avoid that trade.
We send only when there's something worth saying — typically once or twice a month.